XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Restructuring charges/(credits):        
Employee terminations $ 1,014 $ 96 $ 984 $ 61
Asset impairments 41 15 66 4
Exit costs 49 27 63 29
Restructuring charges/(credits) [1] 1,104 138 1,114 94
Transaction costs [2] 0 8 5 8
Integration costs and other [3] 150 68 237 120
Restructuring charges and certain acquisition-related costs 1,254 214 1,356 222
Additional depreciation––asset restructuring [4] 4 4 8 23
Implementation costs [5] 105 98 163 183
Total costs associated with acquisitions and cost-reduction/productivity initiatives 1,364 313 1,532 420
Biopharma [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 1,100   1,100  
Biopharma [Member] | Manufacturing Optimization Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 1,300   1,300  
Biopharma [Member] | Realigning Our Cost Base Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) (113)   (199)  
Other (income)/deductions––net [Member]        
Restructuring charges/(credits):        
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net 2 (2) 5 (7)
Cost of sales [Member]        
Restructuring charges/(credits):        
Additional depreciation––asset restructuring [4] 1 4 5 22
Implementation costs [5] 49 13 65 27
Selling, informational and administrative expenses [Member]        
Restructuring charges/(credits):        
Additional depreciation––asset restructuring [4] 3 0 3 0
Implementation costs [5] 36 67 65 126
Research and development expense [Member]        
Restructuring charges/(credits):        
Implementation costs [5] $ 20 $ 19 $ 33 $ 30
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). Amounts associated with our Biopharma segment for the three and six months ended July 2, 2023 were not material.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.